Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse.

The genes at the INK4A/ARF locus at 9p21 are frequently involved in human cancer. Virtually all p16(INK4A) exon 2 (henceforth called p16) inactivation in pediatric acute lymphoblastic leukemia (ALL) occurs by gene deletion. The results of this study illustrate that real-time quantitative polymerase chain reaction is capable of detecting gene deletion in primary patient specimens with a precision not previously achieved by conventional methods. Importantly, this assay includes the detection of hemizygous deletions. The study revealed, strikingly, that the risk ratio for relapse for hemizygous deletion compared with no deletion was 6.558 (P =.00687) and for homozygous deletion was 11.558 (P =.000539). These results confirm and extend the authors' previous findings that homozygous deletion of p16 in pediatric ALL patients is an independent prognostic indicator of outcome from therapy.

[1]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[2]  Eric R. Ziegel,et al.  Generalized Linear Models , 2002, Technometrics.

[3]  W. Cook,et al.  Accommodating haploinsufficient tumour suppressor genes in Knudson's model , 2000, Oncogene.

[4]  M. Greaves,et al.  Molecular genetics, natural history and the demise of childhood leukaemia. , 1999, European journal of cancer.

[5]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[6]  M. Roussel.  The INK4 family of cell cycle inhibitors in cancer , 1999, Oncogene.

[7]  R. DePinho,et al.  The INK4A/ARF locus and its two gene products. , 1999, Current opinion in genetics & development.

[8]  J. Slingerland,et al.  The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. , 1999, Annual review of medicine.

[9]  S. Lowe,et al.  INK 4 a / ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p 53 , 1999 .

[10]  H. Drexler.  Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cells , 1998, Leukemia.

[11]  P. Burton,et al.  Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. , 1997, Blood.

[12]  D. Grandér,et al.  Prognostic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[14]  J. Sklar,et al.  Sensitive detection of clonal antigen receptor gene rearrangements for the diagnosis and monitoring of lymphoid neoplasms by a polymerase chain reaction-mediated ribonuclease protection assay. , 1991, Blood.

[15]  B. Lange,et al.  Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .